GlassScriptPhysician profile
Peter Ming Zhang
NPI 1821521972
$2,599.80
in general payments reported to CMS, 2019-2025
30 companies · $29.55 in 2025
The $29.55 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $839 · 2023: $1,570 · 2024: $161 · 2025: $29.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $487.76 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $378.63 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $279.88 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $194.04 | 2022-2023 | Otezla, Repatha, Prolia |
| Procept Biorobotics Corporation | $138.37 | 2023 | Aquabeam Robotic System |
| Merck Sharp & Dohme LLC | $138.10 | 2022-2023 | Verquvo, Belsomra, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.85 | 2022-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $127.47 | 2022-2023 | Trelegy Ellipta |
| Abbvie INC. | $77.67 | 2022-2025 | Qulipta, Ubrelvy |
| Nevro Corp. | $57.93 | 2022-2023 | Senza |
| Radius Health, INC. | $57.66 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $54.29 | 2022 | |
| Abbott Laboratories | $47.43 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Becton, Dickinson and Company | $45.00 | 2024 | Bd Introsyte |
| Exact Sciences Corporation | $43.96 | 2023 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $34.93 | 2022 | |
| Bioventus LLC | $32.77 | 2023 | Supartz Fx Sodium Hyaluronate |
| Neurocrine Biosciences, INC. | $24.78 | 2023 | Ingrezza |
| Coopersurgical, INC. | $23.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.14 | 2022 | |
| Sanofi Pasteur INC. | $21.30 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.09 | 2023 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $21.08 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.83 | 2022 | |
| Hologic Sales and Service, LLC | $19.39 | 2023 | Thinprep 2000 Processor, Aptima |
| Amarin Pharma, INC. | $19.24 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.78 | 2023 | |
| Verrica Pharmaceuticals INC. | $18.77 | 2023 | Ycanth |
| Pfizer INC. | $18.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.